rs10264272 CYP3A5
Drug response
What is rs10264272?
rs10264272 is a single-nucleotide polymorphism (SNP) in the CYP3A5 gene (Cytochrome P450 3A5). Each person carries two copies, one from each parent, so a result is reported as a pair of letters such as CT. The table below describes what studies associate with each genotype; the association is statistical, across populations, and is not a diagnosis.
What does each rs10264272 genotype mean?
| Genotype | Association | What the evidence says | Confidence |
|---|
Which drugs have annotations for rs10264272?
PharmGKB clinical annotations (level 1A is the strongest evidence, 4 the weakest):
| Drug | Annotation type | Evidence level |
|---|---|---|
| lumefantrine | Metabolism/PK, Dosage | 3 |
| tacrolimus | Metabolism/PK, Dosage | 3 |
Is rs10264272 on 23andMe and AncestryDNA chips?
Chip coverage is not recorded for this variant. Orviva reports it when a raw-data file contains it directly or via a well-correlated proxy SNP, and says so when it does not.
Sources
- PharmGKB:3
- Drug:lumefantrine
- Type:Metabolism/PK
Upload your 23andMe, AncestryDNA or WeGene raw file → · Ask G2: “What is my genotype at rs10264272 and what does it mean for me?”
Genetic associations describe risk across populations, not a diagnosis for any one person. Most variants shift risk modestly and act alongside lifestyle, environment and other genes. Consumer DNA chips do not read every position and can be wrong at any single one. For general education only; talk to a clinician or genetic counsellor before acting on anything here, and never change a prescribed medicine without your prescriber.